1. Home
  2. CHRS

as 09-08-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Founded: 2010 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 102.0M IPO Year: 2014
Target Price: $4.51 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 1.55 EPS Growth: N/A
52 Week Low/High: $0.66 - $2.43 Next Earning Date: 11-05-2025
Revenue: $272,209,000 Revenue Growth: 52.33%
Revenue Growth (this year): -82.25% Revenue Growth (next year): 126.00%

CHRS Daily Stock ML Predictions

Share on Social Networks: